Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

49.25 +0.62 (+1.27%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

40 41 Next >

EXCLUSIVE: VeeCon 2024 Announces Danica Patrick, Jerome Bettis, Paul Scheer, Mike Posner, Liquid Death CEO Mike Cessario As New Speakers ↗

July 11, 2024

VeeCon will bring the best of business, pop culture and Web3 in a multi-day conference hosted by serial entrepreneur and VeeFriends founder Gary Vaynerchuk (aka Gary Vee) for a

Via Benzinga

3 Stocks to Sell Immediately Based on the French Election Results ↗

July 09, 2024

Discover why Engie S.A., Sanofi, and Carrefour are prime candidates for divestment post-French elections amid potential policy impacts.

Via InvestorPlace

What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients ↗

July 05, 2024

A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.

Via Investor's Business Daily

Upcoming Stock Spinoffs: Should You Pounce or Pass? ↗

July 04, 2024

Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in.

Via InvestorPlace

7 Safe Haven Stocks to Buy Before the Next Market Correction ↗

July 03, 2024

Discover resilient safe haven stocks to weather economic fluctuations in restaurants, pharmaceuticals, household products, and retail.

Via InvestorPlace

Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data ↗

July 03, 2024

EMA approves Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood eosinophils. This marks the first new treatment for COPD in over a...

Via Benzinga

Novavax’s Second Act: How a Fallen COVID Star Could Rise from the Ashes ↗

July 03, 2024

After pulling back following May's "Sanofi surge," don't rule out the potential for further needle-moving news with Novavax stock.

Via InvestorPlace

Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims ↗

July 02, 2024

A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to...

Via Benzinga

Topics Lawsuit

Surprise! 3 Stocks That Are Outperforming Nvidia in 2024. ↗

July 01, 2024

There are more marketplace opportunities than just AI which is why these stocks that are outperforming Nvidia have done so well.

Via InvestorPlace

Topics Artificial Intelligence

Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant ↗

July 01, 2024

Sanofi is set to invest up to $1.6 billion in its Frankfurt insulin production site, marking a significant win for Germany's healthcare sector. Recent investments by Daiichi Sankyo and Eli Lilly...

Via Benzinga

Where Will Novavax Be in 1 Year? ↗

June 29, 2024

We will know a lot more about the vaccine maker's long-term prospects in 12 months.

Via The Motley Fool

First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product ↗

June 27, 2024

The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales.

Via Benzinga

Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today? ↗

June 27, 2024

Vigil Neuroscience stock is up with heavy trading of VIGL shares this morning on news of a $40 million investment from Sanofi.

Via InvestorPlace

Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

June 26, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC ↗

June 26, 2024

Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.

Via Benzinga

Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer ↗

June 20, 2024

GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency.

Via Benzinga

Topics Lawsuit

Is It Too Late to Buy Novavax Stock? ↗

June 14, 2024

Shares of the vaccine maker are trading up 230% this year.

Via The Motley Fool

Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks ↗

June 13, 2024

The companies are closing in on the finish line for two new COPD treatments.

Via Investor's Business Daily

Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club ↗

June 12, 2024

Enthusiasm is growing for a looming approval in COPD treatment.

Via Investor's Business Daily

A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge ↗

June 12, 2024

The integration of AI and healthcare is well underway.

Via The Motley Fool

Topics Artificial Intelligence

Bull Market and Beyond: 3 Stocks Just Waiting to Soar ↗

June 11, 2024

These pharma and biotech players could become long-term winners.

Via The Motley Fool

Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK ↗

June 10, 2024

If approved, this would be the first combination vaccine based on mRNA technology to hit the market.

Via Investor's Business Daily

Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar ↗

June 07, 2024

These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials.

Via InvestorPlace

The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash ↗

June 07, 2024

Dividend stocks have a record of stability and growth. Read here about three picks that are thriving and hiking dividends amid uncertainty.

Via InvestorPlace

Sanofi Highlights Data From Blood Cancer Drug Sarclisa In New Diagnosed Multiple Myeloma Patients ↗

June 04, 2024

Sanofi's phase 3 IMROZ study shows Sarclisa with VRd significantly improves progression-free survival in newly diagnosed, transplant-ineligible multiple myeloma patients.

Via Benzinga

3 Dividend Stocks to Buy in June 2024 for Dependable Dividend Growth ↗

June 03, 2024

Explore three reliable dividend growth stocks for June 2024 to expand your investment profits for the second half of the year.

Via InvestorPlace

Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward ↗

June 03, 2024

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022...

Via Benzinga

Topics Lawsuit

Growth Stocks to Avoid Like the Plague: 3 Overpriced Picks Primed to Plummet ↗

June 01, 2024

These are the overpriced growth stocks to sell and buy after these names corrected by 20% to 30% in the coming quarters.

Via InvestorPlace

FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease ↗

May 31, 2024

The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 2024. This follows the submission of additional efficacy analyses from...

Via Benzinga

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

May 31, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

40 41 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sanofi - American Depositary Shares (NQ:SNY)

All News about Sanofi - American Depositary Shares

Starting at $3.75/week.

Subscribe Today